Related Experiment Videos
Bone marrow transplantation for lymphoma CR1
Corrado Tarella1, Alessandro M Gianni
1Department of Medicina-Oncologia Sp., Divisione Universitaria di Ematologia, Torino, Italy.
Current Opinion in Oncology
|February 24, 2005
Summary
Autologous stem cell transplantation shows survival benefits for high-risk non-Hodgkin lymphoma. Further research is needed to confirm its role as a first-line therapy compared to chemotherapy, especially with new agents like rituximab.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Autologous stem cell transplantation (ASCT) is established for salvage therapy in non-Hodgkin lymphoma (NHL).
- Its role in first-line treatment for NHL remains debated.
- Recent advancements include the integration of novel agents and reduced-intensity allogeneic transplantation.
Purpose of the Study:
- To review recent studies on ASCT for first-line therapy in NHL.
- To evaluate the efficacy of ASCT in different NHL subtypes.
- To discuss the ongoing controversy regarding ASCT versus conventional chemotherapy.
Main Methods:
- Review of recent clinical studies and literature on ASCT in NHL.
- Analysis of survival data and treatment outcomes.
- Comparison of ASCT with conventional chemotherapy and emerging therapies.
Main Results:
- ASCT demonstrates survival benefits in diffuse large cell and follicular lymphomas with poor prognostic features.
- ASCT is a highly effective first-line option for mantle-cell lymphoma.
- The superiority of ASCT over chemotherapy is still under investigation, particularly with the advent of rituximab-based regimens.
- Rituximab may enhance ASCT efficacy as an in vivo purging agent.
- Reduced-intensity allogeneic transplantation offers a rescue option for ASCT non-responders.
Conclusions:
- ASCT is a viable research strategy for first-line NHL therapy.
- Combined with new agents and nonmyeloablative allogeneic transplantation, ASCT can improve cure rates for high-risk NHL.
- Large randomized trials comparing ASCT with chemotherapy, both with rituximab, are necessary to define optimal first-line treatment for CD20+ NHL subtypes.